Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCLAIM-Lp(a): Lepodisiran cardiovascular outcomes study in adults with elevated lipoprotein(a)
2023-509190-23-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Lepodisiran with Placebo (2 arms). Primary endpoint: Time to first occurrence of any component of MACE-4. Planned start Sep 2024; status: authorised.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on 2023-509190-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509190-23-00.